COMMUNIQUÉS West-GlobeNewswire

LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia
24/09/2025
TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Kura Oncology to Participate in Upcoming Investor Conference
24/09/2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
24/09/2025
NAARDEN, The Netherlands and MIAMI, Sept. 24, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Aging in Place, Limited Access to Medical Care and Economic Insecurity Threaten U.S. Senior Health
24/09/2025
New Alignment Health study shows nearly 2 in 5 seniors who experience loneliness say it’s impacting their health, 1 in 4 who have medical debt owe debt equal to 4+ months of living expenses ORANGE, Calif., Sept. 24, [...]
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research
24/09/2025
Engagement Will Expand Daré’s Engagement in Advancing Women’s Health Innovation and Provide Insights into One of the Most Significant Unmet Needs in Maternal Care SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Daré [...]
BPGbio Sponsors MitoAction Energy Walk at Boston’s Franklin Park Zoo on September 27th, 2025
24/09/2025
Company honored in its commitment to patients and families living with mitochondrial disease; invites the community to walk with BPGbio colleagues and MitoAction BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- BPGbio , Inc [...]
MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent
24/09/2025
THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Notification of US Food and Drug Administration Approval of Suitability Petition for NRx’s Proposed Strength of Preservative-Free Ketamine
24/09/2025
Suitability Petition is required for shift from multidose packaging of ketamine to single-patient dose preservative free ketamine Granting of Suitability Petition enables re-filing of Abbreviated New Drug Application ( [...]
EGI Launches Next-Generation HD-EEG Platform to Advance Understanding of Brain Function and Stimulation
24/09/2025
Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- EGI has unveiled the Geodesic EEG System 500, the world’s [...]
Leading CDMO Enhances cGMP Lab Infrastructure to Strengthen Position
24/09/2025
Expanded microbiology lab and analytical chemistry capabilities position Ritedose for accelerated growth. $17+ million investment fuels innovation and scale in drug development. COLUMBIA, S.C., Sept. 24, 2025 (GLOBE [...]
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC)
24/09/2025
Intends to Initiate Phase 1b Clinical Trial in TNBC at Mayo Clinic in Fourth Quarter 2025 FLORHAM PARK, N.J. and LONDON and CHARLOTTESVILLE, Va., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (“ [...]
Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases
24/09/2025
Expanded access will help bring treatments to patients in certain countries within Central and Eastern Europe, the Mediterranean and Eurasia ATHENS, Greece and SOLANA BEACH, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Er [...]
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
24/09/2025
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes
24/09/2025
Funding supports Phase 2b development of clofutriben, a novel HSD-1 inhibitor, with a focus on cortisol-driven metabolic dysfunction in type 2 diabetes PORTLAND, Ore., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sparrow [...]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
24/09/2025
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous Injection SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano, [...]
Ultrack Systems Inc. (OTC: MJLB) Subsidiary Better Pets Secures Canadian Trademark Registration and Advances U.S. Trademark Application
24/09/2025
TORONTO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Ultrack Systems Inc. (OTC: MJLB) (“Ultrack” or the “Company”), through its wholly owned subsidiary Better Pets (Better Health Sciences for Pets Corp.), is pleased to announce [...]
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
24/09/2025
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies have proven to be [...]
OneMedNet Expands Into $1.5B Healthcare Data Annotation Market With MedCase
24/09/2025
MINNEAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leader in AI-powered Real-World Data (RWD), announced a strategic partnership with [...]
Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option
24/09/2025
VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]

Pages